View Filing Data

Document And Entity Information - USD ($)	6 Months Ended
Document And Entity Information - USD ($)	Jun. 30, 2011	Jul. 15, 2011
Entity Registrant Name	REGENERON PHARMACEUTICALS INC
Entity Central Index Key	0000872589
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Large Accelerated Filer
Entity Public Float	$ 1,726,149,000
Entity Common Stock, Shares Outstanding		89,499,900
Document Fiscal Year Focus	2011
Document Fiscal Period Focus	Q2
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2011

CONDENSED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2011	Dec. 31, 2010
Current assets
Cash and cash equivalents	$ 254,312	$ 112,572
Marketable securities	55,371	136,796
Accounts receivable from Sanofi	81,643	79,603
Accounts receivable - other	2,921	13,509
Prepaid expenses and other current assets	19,026	15,142
Total current assets	413,273	357,622
Restricted cash and marketable securities	8,165	7,518
Marketable securities	251,256	370,053
Property, plant, and equipment, at cost, net of accumulated depreciation and amortization	361,883	347,450
Other assets	12,287	6,789
Total assets	1,046,864	1,089,432
Current liabilities
Accounts payable and accrued expenses	81,665	53,658
Deferred revenue from Sanofi, current portion	19,720	19,506
Deferred revenue - other, current portion	33,606	35,217
Facility lease obligations, current portion	877	675
Total current liabilities	135,868	109,056
Deferred revenue from Sanofi	91,712	97,081
Deferred revenue - other	174,987	188,775
Facility lease obligations	159,457	159,355
Other long term liabilities	6,806	7,350
Total liabilities	568,830	561,617
Commitments and contingencies
Stockholders' equity
Preferred stock	0	0
Common Stock	89	87
Additional paid-in capital	1,630,362	1,575,780
Accumulated deficit	(1,151,515)	(1,045,563)
Accumulated other comprehensive loss	(904)	(2,491)
Total stockholders' equity	478,034	527,815
Total liabilities and stockholders' equity	1,046,864	1,089,432
Class A Stock [Member]
Stockholders' equity
Common Stock	$ 2	$ 2

CONDENSED BALANCE SHEETS (Unaudited) Parenthetical - $ / shares	Jun. 30, 2011	Dec. 31, 2010
Stockholders' equity
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	30,000,000	30,000,000
Preferred stock, issued (in shares)	0	0
Preferred stock, outstanding (in shares)	0	0
Common Stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common Stock, shares authorized (in shares)	160,000,000	160,000,000
Common Stock, shares issued (in shares)	89,416,015	87,238,301
Common Stock, shares outstanding (in shares)	89,416,015	87,238,301
Class A Stock [Member]
Stockholders' equity
Common Stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common Stock, shares authorized (in shares)	40,000,000	40,000,000
Common Stock, shares issued (in shares)	2,126,717	2,182,036
Common Stock, shares outstanding (in shares)	2,126,717	2,182,036

CONDENSED STATEMENTS OF OPERATIONS (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2011	Jun. 30, 2010	Jun. 30, 2011	Jun. 30, 2010
Revenues
Sanofi collaboration revenue	$ 84,446	$ 84,941	$ 169,775	$ 153,612
Other collaboration revenue	11,123	13,635	23,604	26,722
Technology licensing	5,228	10,037	13,073	20,075
Net product sales	5,039	5,197	9,466	15,049
Contract research and other	1,974	2,076	4,096	3,962
Total revenues	107,810	115,886	220,014	219,420
Expenses
Research and development	143,149	124,526	272,541	241,997
Selling, general, and administrative	24,585	14,679	47,996	28,902
Cost of goods sold	395	405	777	1,122
Total expenses	168,129	139,610	321,314	272,021
Loss from operations	(60,319)	(23,724)	(101,300)	(52,601)
Other income (expense)
Investment income	998	592	2,035	1,031
Interest expense	(4,047)	(2,342)	(7,766)	(4,426)
Total other income (expense)	(3,049)	(1,750)	(5,731)	(3,395)
Net loss before income tax benefit	(63,368)	(25,474)	(107,031)	(55,996)
Income tax benefit	(863)	0	(1,079)	0
Net loss	$ (62,505)	$ (25,474)	$ (105,952)	$ (55,996)
Net loss per share, basic and diluted	$ (0.69)	$ (0.31)	$ (1.18)	$ (0.69)
Weighted average shares outstanding, basic and diluted	90,436	81,492	89,799	81,330

CONDENSED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) - USD ($) shares in Thousands, $ in Thousands	Total	Class A Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Comprehensive Loss [Member]
Balance at Dec. 31, 2009	$ 396,762	$ 2	$ 79	$ 1,336,732	$ (941,095)	$ 1,044
Balance (in shares) at Dec. 31, 2009		2,245	78,861
Increase (decrease) in stockholders' equity [Roll Forward]
Issuance of Common Stock in connection with exercise of stock options, net of shares tendered	11,392		$ 1	11,391
Issuance of Common Stock in connection with exercise of stock options, net of shares tendered (in shares)			878
Issuance of Common Stock in connection with Company 401(k) Savings Plan contribution	2,867			2,867
Issuance of Common Stock in connection with Company 401(k) Savings Plan contribution (in shares)			111
Issuance of restricted Common Stock under Long-Term Incentive Plan (in shares)			10
Conversion of Class A Stock to Common Stock (in shares)		(63)	63
Stock-based compensation charges	17,541			17,541
Net loss	(55,996)				(55,996)		$ (55,996)
Change in net unrealized gain (loss) on marketable securities	(1,350)					(1,350)	(1,350)
Total comprehensive loss	(57,346)
Balance at Jun. 30, 2010	371,216	$ 2	$ 80	1,368,531	(997,091)	(306)	(57,346)
Balance (in shares) at Jun. 30, 2010		2,182	79,923
Balance at Dec. 31, 2010	527,815	$ 2	$ 87	1,575,780	(1,045,563)	(2,491)
Balance (in shares) at Dec. 31, 2010		2,182	87,238
Increase (decrease) in stockholders' equity [Roll Forward]
Issuance of Common Stock in connection with exercise of stock options, net of shares tendered	23,794		$ 2	23,792
Issuance of Common Stock in connection with exercise of stock options, net of shares tendered (in shares)			2,026
Issuance of Common Stock in connection with Company 401(k) Savings Plan contribution	3,405			3,405
Issuance of Common Stock in connection with Company 401(k) Savings Plan contribution (in shares)			92
Issuance of restricted Common Stock under Long-Term Incentive Plan (in shares)			5
Conversion of Class A Stock to Common Stock (in shares)		(55)	55
Stock-based compensation charges	27,385			27,385
Net loss	(105,952)				(105,952)		(105,952)
Change in net unrealized gain (loss) on marketable securities	1,587					1,587	1,587
Total comprehensive loss	(104,365)
Balance at Jun. 30, 2011	$ 478,034	$ 2	$ 89	$ 1,630,362	$ (1,151,515)	$ (904)	$ (104,365)
Balance (in shares) at Jun. 30, 2011		2,127	89,416

PARENTHETICAL DISCLOSURE TO THE CONDENSED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) - USD ($) $ in Millions	3 Months Ended	6 Months Ended
	Jun. 30, 2011	Jun. 30, 2011
Statement of Stockholders' Equity [Abstract]
Change in net unrealized gain (loss) on marketable securities, net of tax effect	$ 0.9	$ 1.1

CONDENSED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2011	Jun. 30, 2010
Cash flows from operating activities
Net loss	$ (105,952)	$ (55,996)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization	14,880	8,707
Non-cash compensation expense	27,197	17,541
Other non-cash charges and expenses, net	832	1,623
Changes in assets and liabilities
Decrease (increase) in accounts receivable	8,548	(29,628)
(Increase) decrease in prepaid expenses and other assets	(8,158)	1,604
(Decrease) increase in deferred revenue	(20,554)	16,616
Increase in accounts payable, accrued expenses, and other liabilities	38,577	18,105
Total adjustments	61,322	34,568
Net cash used in operating activities	(44,630)	(21,428)
Cash flows from investing activities
Purchases of marketable securities	(15,638)	(222,168)
Sales or maturities of marketable securities	216,631	136,711
Capital expenditures	(37,030)	(45,324)
Increase in restricted cash	(681)	(1,800)
Net cash provided by (used in) investing activities	163,282	(132,581)
Cash flows from financing activities
Proceeds in connection with facility lease obligations	0	47,544
Payments in connection with facility lease obligations	(227)	(674)
Net proceeds from the issuance of Common Stock	23,752	12,064
Payments in connection with capital lease obligation	(437)	0
Net cash provided by financing activities	23,088	58,934
Net increase (decrease) in cash and cash equivalents	141,740	(95,075)
Cash and cash equivalents at beginning of period	112,572	207,075
Cash and cash equivalents at end of period	$ 254,312	$ 112,000

Interim Financial Statements

6 Months Ended

Jun. 30, 2011

Interim Financial Statements [Abstract]

Interim Financial Statements

1.	Interim Financial Statements

The interim Condensed Financial Statements of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") have been prepared in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all information and disclosures necessary for a presentation of the Company's financial position, results of operations, and cash flows in conformity with accounting principles generally accepted in the United States of America. In the opinion of management, these financial statements reflect all adjustments, consisting only of normal recurring accruals, necessary for a fair presentation of the Company's financial position, results of operations, and cash flows for such periods. The results of operations for any interim periods are not necessarily indicative of the results for the full year. The December 31, 2010 Condensed Balance Sheet data were derived from audited financial statements, but do not include all disclosures required by accounting principles generally accepted in the United States of America. These financial statements should be read in conjunction with the financial statements and notes thereto contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2010.

Certain reclassifications have been made to the financial statements for the six months ended June 30, 2010 to conform with the current period's presentation.

- Definition

The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 2-6
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Name Statement of Position (SOP)
-Publisher AICPA
-Number 94-6
-Paragraph 10
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Name FASB Interpretation (FIN)
-Publisher FASB
-Number 46R
-Paragraph 4, 14, 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6359553&loc=d3e288-107754

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2197480

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6921930&loc=d3e5614-111684

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 915
-SubTopic 235
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6472506&loc=d3e38932-110933

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2209116

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 272
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6970148&loc=SL6228881-111685

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2122150

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 720
-SubTopic 15
-URI http://asc.fasb.org/subtopic&trid=2122524

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2134480

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Staff Position (FSP)
-Number FAS140-4/FIN46(R)-8
-Paragraph 8, C1, C7
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

ARCALYST (rilonacept) Product Revenue

6 Months Ended

Jun. 30, 2011

Product Revenue [Abstract]

ARCALYST (rilonacept) Product Revenue

2.	ARCALYST® (rilonacept) Product Revenue

In February 2008, the Company received marketing approval from the U.S. Food and Drug Administration (“FDA”) for ARCALYST® Injection for Subcutaneous Use for the treatment of Cryopyrin-Associated Periodic Syndromes (“CAPS”). The Company had limited historical return experience for ARCALYST® beginning with initial sales in 2008 through the end of 2009; therefore, ARCALYST® net product sales were deferred until the right of return no longer existed and rebates could be reasonably estimated. Effective in the first quarter of 2010, the Company determined that it had accumulated sufficient historical data to reasonably estimate both product returns and rebates of ARCALYST®. As a result, $4.8 million of previously deferred ARCALYST® net product sales were recognized as revenue in the first quarter of 2010. The effect of this change in estimate related to ARCALYST® net product sales revenue was to lower the Company’s net loss per share by $0.06 for the six months ended June 30, 2010.

ARCALYST® net product sales totaled $5.0 million and $5.2 million for the three months ended June 30, 2011 and 2010, respectively, and $9.5 million and $15.0 million for the six months ended June 30, 2011 and 2010, respectively. ARCALYST® net product sales during the first six months of 2010 included $10.2 million of net product sales made during this period and $4.8 million of previously deferred net product sales, as described above. There was no deferred ARCALYST® net product sales revenue at June 30, 2011 or 2010.

Cost of goods sold related to ARCALYST® sales, which consisted primarily of royalties, totaled $0.4 million for both the three months ended June 30, 2011 and 2010, and $0.8 million and $1.1 million for the six months ended June 30, 2011 and 2010, respectively. ARCALYST® shipments to the Company’s customers primarily consisted of supplies of inventory manufactured and expensed as research and development costs prior to 2008; therefore, the costs of these supplies were not included in costs of goods sold.

Per Share Data

6 Months Ended

Jun. 30, 2011

Per Share Data [Abstract]

Per Share Data

3.	Per Share Data

The Company's basic and diluted net loss per share amounts have been computed by dividing net loss by the weighted average number of shares of Common Stock and Class A Stock outstanding. Net loss per share is presented on a combined basis, inclusive of Common Stock and Class A Stock outstanding, as each class of stock has equivalent economic rights. For the three and six months ended June 30, 2011 and 2010, the Company reported net losses; therefore, no common stock equivalents were included in the computation of diluted net loss per share for these periods, since such inclusion would have been antidilutive. The calculations of basic and diluted net loss per share are as follows:

	Three Months Ended June 30,
	2011	2010
Net loss (Numerator)	$(62,505)	$(25,474)

Weighted-average shares, in thousands (Denominator)	90,436	81,492

Basic and diluted net loss per share	$(0.69)	$(0.31)

	Six Months Ended June 30,
	2011	2010
Net loss (Numerator)	$(105,952)	$(55,996)

Weighted-average shares, in thousands (Denominator)	89,799	81,330

Basic and diluted net loss per share	$(1.18)	$(0.69)

Shares issuable upon the exercise of stock options and vesting of restricted stock awards, which have been excluded from the June 30, 2011 and 2010 diluted per share amounts because their effect would have been antidilutive, include the following:

	Three months ended June 30,
	2011	2010
Stock Options:
Weighted average number, in thousands	20,967	21,288
Weighted average exercise price	$20.71	$18.67

Restricted Stock:
Weighted average number, in thousands	846	510

	Six months ended June 30,
	2011	2010
Stock Options:
Weighted average number, in thousands	21,668	21,344
Weighted average exercise price	$20.48	$18.63

Restricted Stock:
Weighted average number, in thousands	846	506

Statement of Cash Flows

6 Months Ended

Jun. 30, 2011

Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]

Statement of Cash Flows

4.	Statement of Cash Flows

Supplemental disclosure of noncash investing and financing activities:

Included in accounts payable and accrued expenses at June 30, 2011 and December 31, 2010 were $3.4 million and $10.7 million, respectively, of accrued capital expenditures. Included in accounts payable and accrued expenses at June 30, 2010 and December 31, 2009 were $4.1 million and $9.8 million, respectively, of accrued capital expenditures.

Included in accounts payable and accrued expenses at December 31, 2010 and 2009 were $2.9 million and $2.6 million, respectively, of accrued Company 401(k) Savings Plan contribution expense. In the first quarter of 2011 and 2010, the Company contributed 91,761 and 111,419 shares, respectively, of Common Stock to the 401(k) Savings Plan in satisfaction of these obligations.

Included in facility lease obligations and property, plant, and equipment at June 30, 2010 was $1.7 million of capitalized and deferred interest for the six months ended June 30, 2010, as the related facilities being leased by the Company were under construction and lease payments on these facilities did not commence until January 2011.

The Company incurred capital lease obligations of $0.7 million during the six months ended June 30, 2011 in connection with acquisitions of equipment.

Included in marketable securities at June 30, 2011 and December 31, 2010 were $0.8 million and $1.4 million, respectively, of accrued interest income. Included in marketable securities at June 30, 2010 and December 31, 2009 were $1.3 million and $0.6 million, respectively, of accrued interest income.

Marketable Securities

6 Months Ended

Jun. 30, 2011

Marketable Securities [Abstract]

Marketable Securities

5.	Marketable Securities

Marketable securities at June 30, 2011 and December 31, 2010 consisted of debt securities, as detailed below, and equity securities. The aggregate fair value of the equity securities was $4.3 million and $3.6 million at June 30, 2011 and December 31, 2010, respectively, and the aggregate cost basis was $4.0 million at both June 30, 2011 and December 31, 2010. The Company also held restricted marketable securities at both June 30, 2011 and December 31, 2010, which consisted of debt securities, as detailed below, that collateralize letters of credit and lease obligations.

The following tables summarize the amortized cost basis of debt securities included in marketable securities, the aggregate fair value of those securities, and gross unrealized gains and losses on those securities at June 30, 2011 and December 31, 2010. The Company classifies its debt securities, other than mortgage-backed securities, based on their contractual maturity dates. Maturities of mortgage-backed securities have been estimated based primarily on repayment characteristics and experience of the senior tranches that the Company holds.

	Amortized	Fair	Unrealized
At June 30, 2011	Cost Basis	Value	Gains	(Losses)	Net
Unrestricted
Maturities within one year
U.S. government obligations	$9,142	$9,159	$17		$17
U.S. government guaranteed corporate bonds	31,936	32,088	152		152
U.S. government guaranteed collateralized mortgage obligations	1,321	1,322	1		1
Municipal bonds	12,712	12,730	19	$ (1)	18
Mortgage-backed securities	73	72		(1)	(1)
	55,184	55,371	189	(2)	187
Maturities between one and five years
U.S. government obligations	227,542	228,070	551	(23)	528
U.S. government guaranteed corporate bonds	15,393	15,408	15		15
Municipal bonds	3,310	3,323	13		13
Mortgage-backed securities	275	135		(140)	(140)
	246,520	246,936	579	(163)	416

	301,704	302,307	768	(165)	603

Restricted
Maturities within one year
U.S. government obligations	2,888	2,889	1		1
Maturities between one and three years
U.S. government obligations	5,176	5,182	8	(2)	6
	8,064	8,071	9	(2)	7

	$309,768	$310,378	$777	$(167)	$610

At December 31, 2010
Unrestricted
Maturities within one year
U.S. government obligations	$83,635	$83,684	$54	$(5)	$49
U.S. government guaranteed corporate bonds	48,173	48,531	358		358
U.S. government guaranteed collateralized mortgage obligations	2,027	2,131	104		104
Municipal bonds	1,597	1,603	6		6
Mortgage-backed securities	875	847		(28)	(28)
	136,307	136,796	522	(33)	489

Maturities between one and five years
U.S. government obligations	352,345	350,683	64	(1,726)	(1,662)
U.S. government guaranteed corporate bonds	15,522	15,477		(45)	(45)
Mortgage-backed securities	110	38		(72)	(72)
	367,977	366,198	64	(1,843)	(1,779)
Maturities between five and seven years
Mortgage-backed securities	284	243		(41)	(41)
	504,568	503,237	586	(1,917)	(1,331)

Restricted
Maturities within one year
U.S. government obligations	2,922	2,921		(1)	(1)

Maturities between one and three years
U.S. government obligations	4,135	4,118		(17)	(17)
	7,057	7,039		(18)	(18)

	$511,625	$510,276	$586	$(1,935)	$(1,349)

At June 30, 2011 and December 31, 2010, marketable securities included an additional unrealized gain of $0.3 million and an unrealized loss of $0.4 million, respectively, related to one equity security in the Company's marketable securities portfolio.

The following table shows the fair value of the Company's marketable securities that have unrealized losses and that are deemed to be only temporarily impaired, aggregated by investment category and length of time that the individual securities have been in a continuous unrealized loss position, at June 30, 2011 and December 31, 2010. The debt securities held at June 30, 2011, excluding mortgage-backed securities, mature at various dates through December 2013. The mortgage-backed securities held at June 30, 2011 have various estimated maturity dates through July 2015.

	Less than 12 Months		12 Months or Greater		Total
At June 30, 2011	Fair Value	Unrealized Loss	Fair Value	Unrealized Loss	Fair Value	Unrealized Loss
Unrestricted
U.S. government obligations	$25,649	$(23)			$25,649	$(23)
Municipal bonds	3,264	(1)			3,264	(1)
Mortgage-backed securities			$207	$(141)	207	(141)
	28,913	(24)	207	(141)	29,120	(165)

Restricted
U.S. government obligations	1,431	(2)			1,431	(2)
	1,431	(2)			1,431	(2)

	$30,344	$(26)	$207	$(141)	$30,551	$(167)

	Less than 12 Months		12 Months or Greater		Total
At December 31, 2010	Fair Value	Unrealized Loss	Fair Value	Unrealized Loss	Fair Value	Unrealized Loss
Unrestricted
U.S. government obligations	$340,444	$(1,731)			$340,444	$(1,731)
U.S. government guaranteed corporate bonds	19,005	(45)			19,005	(45)
Equity securities	3,612	(433)			3,612	(433)
Mortgage-backed securities			$1,128	$(141)	1,128	(141)
	363,061	(2,209)	1,128	(141)	364,189	(2,350)

Restricted
U.S. government obligations	6,154	(18)			6,154	(18)
	6,154	(18)			6,154	(18)

	$369,215	$(2,227)	$1,128	$(141)	$370,343	$(2,368)

Realized gains and losses are included as a component of investment income. For the three and six months ended June 30, 2011 and 2010, realized gains and losses on sales of marketable securities were not significant. In computing realized gains and losses, the Company computes the cost of its investments on a specific identification basis. Such cost includes the direct costs to acquire the security, adjusted for the amortization of any discount or premium.

The Company's assets that are measured at fair value on a recurring basis, at June 30, 2011 and December 31, 2010, were as follows:

		Fair Value Measurements at Reporting Date Using
	Fair Value	Quoted Prices in Active Markets for Identical Assets (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)
At June 30, 2011
Unrestricted
Available-for-sale marketable securities
U.S. government obligations	$237,229		$237,229
U.S. government guaranteed corporate bonds	47,496		47,496
U.S. government guaranteed collateralized mortgage obligations	1,322		1,322
Municipal bonds	16,053		16,053
Mortgage-backed securities	207		207
Equity securities	4,320	$4,320
	306,627	4,320	302,307

Restricted
Available-for-sale marketable securities
U.S. government obligations	8,071		8,071

	$314,698	$4,320	$310,378

		Fair Value Measurements at Reporting Date Using
	Fair Value	Quoted Prices in Active Markets for Identical Assets (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)
At December 31, 2010
Unrestricted
Available-for-sale marketable securities
U.S. government obligations	$434,367		$434,367
U.S. government guaranteed corporate bonds	64,008		64,008
U.S. government guaranteed collateralized mortgage obligations	2,131		2,131
Municipal bonds	1,603		1,603
Mortgage-backed securities	1,128		1,128
Equity securities	3,612	$3,612
	506,849	3,612	503,237

Restricted
Available-for-sale marketable securities
U.S. government obligations	7,039		7,039

	$513,888	$3,612	$510,276

Marketable securities included in Level 2 were valued using a market approach utilizing prices and other relevant information, such as interest rates, yield curves, prepayment speeds, loss severities, credit risks and default rates, generated by market transactions involving identical or comparable assets. The Company considers market liquidity in determining the fair value for these securities. During the six months ended June 30, 2010, deterioration in the credit quality of a marketable security from one issuer subjected the Company to the risk of not being able to recover a portion of the security's carrying value. As a result, the Company recognized a $0.1 million impairment charge related to this Level 2 marketable security, which the Company considered to be other-than-temporarily impaired. During the three and six months ended June 30, 2011, and the three months ended June 30, 2010, the Company did not record any charges for other-than-temporary impairment of its Level 2 marketable securities.

The Company holds one Level 3 marketable security, which had no fair value at June 30, 2011 and December 31, 2010. This Level 3 security was valued using information provided by the Company's investment advisors and other sources, including quoted bid prices which took into consideration the security's lack of liquidity. There were no purchases, sales, or maturities of Level 3 marketable securities and no unrealized gains or losses related to Level 3 marketable securities for the three and six months ended June 30, 2011 and 2010. There were no transfers of marketable securities between Levels 1, 2, or 3 classifications during the three and six months ended June 30, 2011 and 2010.

On a quarterly basis, the Company reviews its portfolio of marketable securities, using both quantitative and qualitative factors, to determine if declines in fair value below cost are other-than-temporary. With respect to debt securities, this review process also includes an evaluation of the Company's (a) intent to sell an individual debt security or (b) need to sell the debt security before its anticipated recovery or maturity. With respect to equity securities, this review process includes an evaluation of the Company's ability and intent to hold the securities until their full value can be recovered.

Inventory

6 Months Ended

Jun. 30, 2011

Inventory [Abstract]

Inventory

Inventories as of June 30, 2011 and December 31, 2010 consist of the following:

	June 30, 2011	December 31, 2010
Raw materials	$223	$592
Work in process	6,188	699
Finished goods	131	132
	$6,542	$1,423

At June 30, 2011, $0.6 million of inventories were included in prepaid expenses and other current assets and $5.9 million of inventories were included in other assets. At December 31, 2010, inventories were included in prepaid expenses and other current assets.

Accounts Payable and Accrued Expenses

6 Months Ended

Jun. 30, 2011

Accounts Payable and Accrued Expenses [Abstract]

Accounts Payable and Accrued Expenses

7.	Accounts Payable and Accrued Expenses

Accounts payable and accrued expenses as of June 30, 2011 and December 31, 2010 consist of the following:

	June 30, 2011	December 31, 2010
Accounts payable	$25,955	$15,589
Accrued payroll and related costs	26,029	12,025
Accrued clinical trial expense	9,802	9,727
Accrued property, plant, and equipment costs	1,057	7,622
Other accrued expenses and liabilities	7,810	6,441
Payable to Bayer HealthCare LLC	11,012	2,254
	$81,665	$53,658

Comprehensive Loss

6 Months Ended

Jun. 30, 2011

Comprehensive Loss [Abstract]

Comprehensive Loss

8.	Comprehensive Loss

Comprehensive loss of the Company includes net loss adjusted for the change in net unrealized gain (loss) on marketable securities, net of any tax effect. For the three and six months ended June 30, 2011 and 2010, the components of comprehensive loss are:

	Three months ended June 30,
	2011	2010
Net loss	$(62,505)	$(25,474)
Change in net unrealized gain (loss) on marketable securities, net of tax effect of $0.9 million in 2011	1,271	(1,023)
Total comprehensive loss	$(61,234)	$(26,497)

	Six months ended June 30,
	2011	2010
Net loss	$(105,952)	$(55,996)
Change in net unrealized gain (loss) on marketable securities, net of tax effect of $1.1 million in 2011	1,587	(1,350)
Total comprehensive loss	$(104,365)	$(57,346)

- Definition

The entire disclosure for comprehensive income. Includes, but is not limited to, the following: 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income. Components of comprehensive income include: (1) foreign currency translation adjustments; (2) gains (losses) on foreign currency transactions that are designated as, and are effective as, economic hedges of a net investment in a foreign entity; (3) gains (losses) on intercompany foreign currency transactions that are of a long-term-investment nature, when the entities to the transaction are consolidated, combined, or accounted for by the equity method in the reporting enterprise's financial statements; (4) change in the market value of a futures contract that qualifies as a hedge of an asset reported at fair value; (5) unrealized holding gains (losses) on available-for-sale securities and that resulting from transfers of debt securities from the held-to-maturity category to the available-for-sale category; (6) a net loss recognized as an additional pension liability not yet recognized as net periodic pension cost; and (7) the net gain (loss) and net prior service cost or credit for pension plans and other postretirement benefit plans.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 130
-Paragraph 14-26
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e637-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e681-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e653-108580

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e709-108580

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 55
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6920433&loc=d3e998-108581

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e640-108580

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Reclassification Adjustments
-URI http://asc.fasb.org/extlink&oid=6522872

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e716-108580

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e689-108580

+ Details

Income Taxes

6 Months Ended

Jun. 30, 2011

Income Taxes [Abstract]

Income Taxes

9.	Income Taxes

For the three and six months ended June 30, 2011 and 2010, the Company incurred net losses for tax purposes and recognized a full valuation allowance against deferred tax assets. For the three and six months ended June 30, 2011, the Company recognized an income tax benefit of $0.9 million and $1.1 million, respectively, in connection with the net tax effect of the decrease in the Company's unrealized loss on "available-for-sale" marketable securities, which is included in other comprehensive loss. For the three and six months ended June 30, 2010, no provision or benefit for income taxes was recorded.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph h
-Article 4

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 136, 172
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 43, 44, 45, 46, 47, 48, 49
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32718-109319

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32559-109319

+ Details

Legal Matters	6 Months Ended
Legal Matters	Jun. 30, 2011
Legal Matters [Abstract]
Legal Matters	10. Legal Matters From time to time, the Company is a party to legal proceedings in the course of the Company's business. The Company does not expect any such current ordinary course legal proceedings to have a material adverse effect on the Company's business or financial condition. Costs associated with the Company's involvement in legal proceedings are expensed as incurred. As previously reported, on November 19, 2010, the Company filed a complaint against Genentech in the U.S. District Court for the Southern District of New York seeking a declaratory judgment that no activities relating to the Company's VEGF Trap infringe any valid claim of certain Genentech patents referred to as the Davis-Smyth patents. On January 12, 2011, Genentech filed a motion to dismiss the complaint, arguing that the lawsuit was premature and thus the Court lacked subject matter jurisdiction. Upon the Company's submission to the FDA of a BLA for EYLEATM (also known as VEGF Trap-Eye) for the treatment of wet AMD, the Company filed a second complaint against Genentech in the same court seeking the same declaratory relief. On April 7, 2011, the Company and Genentech entered into a Joint Stipulation, which was approved and executed by the Court on April 11, 2011. Pursuant to the Joint Stipulation, the Company voluntarily dismissed its original complaint in favor of proceeding with its second complaint, and Genentech agreed that it would not seek to transfer the case to another judicial district or move to dismiss the second complaint for lack of subject matter jurisdiction or otherwise under Rule 12(b) of the Federal Rules of Civil Procedure. On April 25, 2011, Genentech filed an answer to the second complaint, denying that the Company is entitled to the declaratory relief being sought by the Company, and asserting counterclaims that the Company's prior or planned activities relating to VEGF Trap have infringed or will infringe one or more claims of the Davis-Smyth patents. In its answer, Genentech requests a judgment against the Company for damages, including for willful infringement, and other relief as the Court deems appropriate. On May 11, 2011, Genentech filed an amended answer and counterclaim, again denying that the Company is entitled to the declaratory relief being sought by the Company, and asserting counterclaims that the Company's prior or planned activities relating to VEGF Trap have infringed or will infringe claims of four of the five Davis-Smyth patents. In its amended answer and counterclaim, Genentech requests a judgment against the Company for damages, including for willful infringement, and other relief as the Court deems appropriate. On May 25, 2011, the Company replied to Genentech's amended answer and counterclaim, denying Genentech's counterclaims, and denying that any of the Company's prior or planned activities relating to VEGF Trap infringe any valid claim of the Davis-Smyth patents. The Company believes Genentech's counterclaims are without merit and intends to continue to defend against them vigorously. As this litigation is at an early stage, at this time the Company is not able to predict the probability of the outcome or an estimate of loss, if any, related to this matter. The Company has initiated patent-related actions against Genentech in Germany and the United Kingdom, and may initiate other actions in other countries outside the U.S.

- Definition

The entire disclosure for commitments and contingencies.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Interpretation (FIN)
-Number 14
-Paragraph 3
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 5
-Paragraph 9, 10, 11, 12
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.25)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6952336&loc=d3e14435-108349

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 460
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6398077&loc=d3e12565-110249

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

+ Details

Recently Issued Accounting Standards

6 Months Ended

Jun. 30, 2011

New Accounting Pronouncements and Changes in Accounting Principles [Abstract]

Recently Issued Accounting Standards

11.	Recently Issued Accounting Standards

Multiple-deliverable revenue arrangements

During the first quarter of 2011 the Company adopted amended authoritative guidance issued by the Financial Accounting Standards Board ("FASB") on multiple-deliverable revenue arrangements. The amended guidance provides greater ability to separate and allocate consideration to be received in a multiple-deliverable revenue arrangement by requiring the use of estimated selling prices to allocate the consideration, thereby eliminating the use of the residual method of allocation. The amended guidance also requires expanded qualitative and quantitative disclosures surrounding multiple-deliverable revenue arrangements. The Company is applying this amended guidance prospectively for new or materially modified arrangements, of which there were none during the six months ended June 30, 2011. The adoption of this guidance did not have a material impact on the Company's financial statements.

Milestone method of revenue recognition

During the first quarter of 2011, the Company adopted amended authoritative guidance issued by the FASB codifying the milestone method of revenue recognition as an acceptable revenue recognition model when a milestone is deemed to be substantive. Since the Company has historically accounted for milestones under the milestone method, the adoption of this guidance did not have a material impact on the Company's financial statements.

In accordance with the Company's accounting policy for recognition of revenue in connection with collaboration agreements, as previously disclosed in the Company's financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2010, payments which are based on achieving a specific performance milestone, involving a degree of risk, are recognized as revenue when the milestone is achieved and the related payment is due and non-refundable, provided there is no future service obligation associated with that milestone. Substantive performance milestones typically consist of significant achievements in the development life-cycle of the related product candidate, such as completion of clinical trials, filing for approval with regulatory agencies, and receipt of approvals by regulatory agencies. In determining whether a payment is deemed to be a substantive performance milestone, the Company takes into consideration (i) the nature, timing, and value of significant achievements in the development life-cycle of the related development product candidate, (ii) the relative level of effort required to achieve the milestone, and (iii) the relative level of risk in achieving the milestone, taking into account the high degree of uncertainty in successfully advancing product candidates in a drug development program and in ultimately attaining an approved drug product. Payments for achieving milestones which are not considered substantive are accounted for as license payments and recognized over the related performance period.

The Company earns substantive performance milestone payments in connection with its collaboration agreements to develop and commercialize product candidates with Sanofi and Bayer HealthCare. Descriptions of these collaboration agreements, including various financial terms and conditions, were provided in the Company's financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2010. Under the Company's collaboration agreement with Sanofi to jointly develop and commercialize ZALTRAPTM (aflibercept, also known as VEGF Trap), the Company may receive up to $400 million in substantive milestone payments upon receipt of specified marketing approvals, including up to $360 million in milestone payments related to the receipt of marketing approvals for up to eight ZALTRAPTM oncology and other indications in the U.S. or the European Union and up to $40 million related to the receipt of marketing approvals for up to five ZALTRAPTM oncology indications in Japan. Under the Company's global, strategic collaboration with Sanofi to discover, develop, and commercialize fully human monoclonal antibodies, for each drug candidate identified under the collaboration's Discovery and Preclinical Development Agreement, Sanofi has the option to license rights to the candidate under the collaboration's License and Collaboration Agreement and co-develop the drug candidate with the Company through product approval. Under certain defined circumstances, upon exercising its option to license rights to particular candidates, Sanofi must make a $10 million substantive milestone payment to the Company. Under the Company's license and collaboration agreement with Bayer HealthCare to globally develop, and commercialize outside the U.S., EYLEATM, the Company is eligible to receive up to $50 million in future substantive milestone payments related to marketing approvals of EYLEATM in major market countries outside the U.S.

Fees paid to the federal government by pharmaceutical manufacturers

In December 2010, the FASB provided authoritative guidance on how pharmaceutical manufacturers should recognize and classify in their income statement annual fees mandated by the Patient Protection and Affordable Care Act as amended by the Health Care and Education Reconciliation Act. This guidance became effective for calendar years beginning after December 31, 2010. The adoption of this guidance did not have an impact on the Company's financial statements as the fee does not currently apply to the Company. The Company's marketed product, ARCALYST� for the treatment of CAPS, has been approved as an orphan drug and orphan drugs are not subject to this annual fee.

Presentation of comprehensive income

In June 2011, the FASB amended its authoritative guidance on the presentation of comprehensive income. Under the amendment, an entity will have the option to present the total of comprehensive income, the components of net income, and the components of other comprehensive income either in a single continuous statement of comprehensive income or in two separate but consecutive statements. This amendment, therefore, eliminates the currently available option to present the components of other comprehensive income as part of the statement of changes in stockholders' equity. The amendment does not change the items that must be reported in other comprehensive income or when an item of other comprehensive income must be reclassified to net income. The Company will adopt this amended guidance for the fiscal year beginning January 1, 2012. As this guidance relates to presentation only, the adoption of this guidance will not have any other effect on the Company's financial statements.

- Definition

Tabular disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 154
-Paragraph 2, 17, 18
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 28
-Paragraph 23, 24
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 01
-Paragraph b
-Subparagraph 6
-Article 10

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6801783&loc=d3e22499-107794

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6801783&loc=d3e22580-107794

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Indirect Effects of a Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=6515603

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Accounting Change
-URI http://asc.fasb.org/extlink&oid=6503790

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=6507316

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Direct Effects of a Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=6510796

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.10-01.(b)(6))
-URI http://asc.fasb.org/extlink&oid=6958853&loc=d3e46468-122699

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6801783&loc=d3e22583-107794

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Retrospective Application
-URI http://asc.fasb.org/extlink&oid=6523989

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=6372559&loc=d3e725-108305

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=6372559&loc=d3e765-108305

+ Details

ARCALYST (rilonacept) Product Revenue (Policies)	6 Months Ended
ARCALYST (rilonacept) Product Revenue (Policies)	Jun. 30, 2011
Product Revenue [Abstract]
Revenue recognition, deferred revenue	The Company had limited historical return experience for ARCALYST® beginning with initial sales in 2008 through the end of 2009; therefore, ARCALYST® net product sales were deferred until the right of return no longer existed and rebates could be reasonably estimated. Effective in the first quarter of 2010, the Company determined that it had accumulated sufficient historical data to reasonably estimate both product returns and rebates of ARCALYST®.

Marketable Securities (Policies)	6 Months Ended
Marketable Securities (Policies)	Jun. 30, 2011
Marketable Securities [Abstract]
Marketable Securities Impairment Policy	On a quarterly basis, the Company reviews its portfolio of marketable securities, using both quantitative and qualitative factors, to determine if declines in fair value below cost are other-than-temporary. With respect to debt securities, this review process also includes an evaluation of the Company's (a) intent to sell an individual debt security or (b) need to sell the debt security before its anticipated recovery or maturity. With respect to equity securities, this review process includes an evaluation of the Company's ability and intent to hold the securities until their full value can be recovered.

- Definition

Disclosure of accounting policy for investments in debt and equity securities that are classified as available-for-sale. This policy also may describe the entity's accounting treatment for transfers between investment categories, how the entity determines whether impairments of available-for-sale securities are other than temporary, and how the fair values of such securities are determined.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 5
-Section M

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 10, 11
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 2, 12
-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Staff Position (FSP)
-Number FAS115-1/124-1
-Paragraph 7, 8, 9, 13, 14, 15, 16, 17
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 115
-Paragraph 12, 13, 14, 15, 16
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2196929

+ Details

Per Share Data (Tables)

6 Months Ended

Jun. 30, 2011

Per Share Data [Abstract]

Basic and diluted net loss per share

The calculations of basic and diluted net loss per share are as follows:

	Three Months Ended June 30,
	2011	2010
Net loss (Numerator)	$(62,505)	$(25,474)

Weighted-average shares, in thousands (Denominator)	90,436	81,492

Basic and diluted net loss per share	$(0.69)	$(0.31)

	Six Months Ended June 30,
	2011	2010
Net loss (Numerator)	$(105,952)	$(55,996)

Weighted-average shares, in thousands (Denominator)	89,799	81,330

Basic and diluted net loss per share	$(1.18)	$(0.69)

Antidilutive securities

	Three months ended June 30,
	2011	2010
Stock Options:
Weighted average number, in thousands	20,967	21,288
Weighted average exercise price	$20.71	$18.67

Restricted Stock:
Weighted average number, in thousands	846	510

	Six months ended June 30,
	2011	2010
Stock Options:
Weighted average number, in thousands	21,668	21,344
Weighted average exercise price	$20.48	$18.63

Restricted Stock:
Weighted average number, in thousands	846	506

Marketable Securities (Tables)

6 Months Ended

Jun. 30, 2011

Marketable Securities [Abstract]

Marketable securities, based on contractual maturity dates

	Amortized	Fair	Unrealized
At June 30, 2011	Cost Basis	Value	Gains	(Losses)	Net
Unrestricted
Maturities within one year
U.S. government obligations	$9,142	$9,159	$17		$17
U.S. government guaranteed corporate bonds	31,936	32,088	152		152
U.S. government guaranteed collateralized mortgage obligations	1,321	1,322	1		1
Municipal bonds	12,712	12,730	19	$ (1)	18
Mortgage-backed securities	73	72		(1)	(1)
	55,184	55,371	189	(2)	187
Maturities between one and five years
U.S. government obligations	227,542	228,070	551	(23)	528
U.S. government guaranteed corporate bonds	15,393	15,408	15		15
Municipal bonds	3,310	3,323	13		13
Mortgage-backed securities	275	135		(140)	(140)
	246,520	246,936	579	(163)	416

	301,704	302,307	768	(165)	603

Restricted
Maturities within one year
U.S. government obligations	2,888	2,889	1		1
Maturities between one and three years
U.S. government obligations	5,176	5,182	8	(2)	6
	8,064	8,071	9	(2)	7

	$309,768	$310,378	$777	$(167)	$610

At December 31, 2010
Unrestricted
Maturities within one year
U.S. government obligations	$83,635	$83,684	$54	$(5)	$49
U.S. government guaranteed corporate bonds	48,173	48,531	358		358
U.S. government guaranteed collateralized mortgage obligations	2,027	2,131	104		104
Municipal bonds	1,597	1,603	6		6
Mortgage-backed securities	875	847		(28)	(28)
	136,307	136,796	522	(33)	489

Maturities between one and five years
U.S. government obligations	352,345	350,683	64	(1,726)	(1,662)
U.S. government guaranteed corporate bonds	15,522	15,477		(45)	(45)
Mortgage-backed securities	110	38		(72)	(72)
	367,977	366,198	64	(1,843)	(1,779)
Maturities between five and seven years
Mortgage-backed securities	284	243		(41)	(41)
	504,568	503,237	586	(1,917)	(1,331)

Restricted
Maturities within one year
U.S. government obligations	2,922	2,921		(1)	(1)

Maturities between one and three years
U.S. government obligations	4,135	4,118		(17)	(17)
	7,057	7,039		(18)	(18)

	$511,625	$510,276	$586	$(1,935)	$(1,349)

Fair value and unrealized losses of marketable securities

	Less than 12 Months		12 Months or Greater		Total
At June 30, 2011	Fair Value	Unrealized Loss	Fair Value	Unrealized Loss	Fair Value	Unrealized Loss
Unrestricted
U.S. government obligations	$25,649	$(23)			$25,649	$(23)
Municipal bonds	3,264	(1)			3,264	(1)
Mortgage-backed securities			$207	$(141)	207	(141)
	28,913	(24)	207	(141)	29,120	(165)

Restricted
U.S. government obligations	1,431	(2)			1,431	(2)
	1,431	(2)			1,431	(2)

	$30,344	$(26)	$207	$(141)	$30,551	$(167)

	Less than 12 Months		12 Months or Greater		Total
At December 31, 2010	Fair Value	Unrealized Loss	Fair Value	Unrealized Loss	Fair Value	Unrealized Loss
Unrestricted
U.S. government obligations	$340,444	$(1,731)			$340,444	$(1,731)
U.S. government guaranteed corporate bonds	19,005	(45)			19,005	(45)
Equity securities	3,612	(433)			3,612	(433)
Mortgage-backed securities			$1,128	$(141)	1,128	(141)
	363,061	(2,209)	1,128	(141)	364,189	(2,350)

Restricted
U.S. government obligations	6,154	(18)			6,154	(18)
	6,154	(18)			6,154	(18)

	$369,215	$(2,227)	$1,128	$(141)	$370,343	$(2,368)

Fair value, assets measured on recurring basis

The Company's assets that are measured at fair value on a recurring basis, at June 30, 2011 and December 31, 2010, were as follows:

		Fair Value Measurements at Reporting Date Using
	Fair Value	Quoted Prices in Active Markets for Identical Assets (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)
At June 30, 2011
Unrestricted
Available-for-sale marketable securities
U.S. government obligations	$237,229		$237,229
U.S. government guaranteed corporate bonds	47,496		47,496
U.S. government guaranteed collateralized mortgage obligations	1,322		1,322
Municipal bonds	16,053		16,053
Mortgage-backed securities	207		207
Equity securities	4,320	$4,320
	306,627	4,320	302,307

Restricted
Available-for-sale marketable securities
U.S. government obligations	8,071		8,071

	$314,698	$4,320	$310,378

		Fair Value Measurements at Reporting Date Using
	Fair Value	Quoted Prices in Active Markets for Identical Assets (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)
At December 31, 2010
Unrestricted
Available-for-sale marketable securities
U.S. government obligations	$434,367		$434,367
U.S. government guaranteed corporate bonds	64,008		64,008
U.S. government guaranteed collateralized mortgage obligations	2,131		2,131
Municipal bonds	1,603		1,603
Mortgage-backed securities	1,128		1,128
Equity securities	3,612	$3,612
	506,849	3,612	503,237

Restricted
Available-for-sale marketable securities
U.S. government obligations	7,039		7,039

	$513,888	$3,612	$510,276

- Definition

Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).

+ References + Details

Inventory (Tables)

6 Months Ended

Jun. 30, 2011

Inventory [Abstract]

Inventories

Inventories as of June 30, 2011 and December 31, 2010 consist of the following:

	June 30, 2011	December 31, 2010
Raw materials	$223	$592
Work in process	6,188	699
Finished goods	131	132
	$6,542	$1,423

Accounts Payable and Accrued Expenses (Tables)

6 Months Ended

Jun. 30, 2011

Accounts Payable and Accrued Expenses [Abstract]

Accounts payable and accrued expenses

Accounts payable and accrued expenses as of June 30, 2011 and December 31, 2010 consist of the following:

	June 30, 2011	December 31, 2010
Accounts payable	$25,955	$15,589
Accrued payroll and related costs	26,029	12,025
Accrued clinical trial expense	9,802	9,727
Accrued property, plant, and equipment costs	1,057	7,622
Other accrued expenses and liabilities	7,810	6,441
Payable to Bayer HealthCare LLC	11,012	2,254
	$81,665	$53,658

Comprehensive Loss (Tables)

6 Months Ended

Jun. 30, 2011

Comprehensive Loss [Abstract]

Components of comprehensive loss, net of tax

For the three and six months ended June 30, 2011 and 2010, the components of comprehensive loss are:

	Three months ended June 30,
	2011	2010
Net loss	$(62,505)	$(25,474)
Change in net unrealized gain (loss) on marketable securities, net of tax effect of $0.9 million in 2011	1,271	(1,023)
Total comprehensive loss	$(61,234)	$(26,497)

	Six months ended June 30,
	2011	2010
Net loss	$(105,952)	$(55,996)
Change in net unrealized gain (loss) on marketable securities, net of tax effect of $1.1 million in 2011	1,587	(1,350)
Total comprehensive loss	$(104,365)	$(57,346)

ARCALYST (rilonacept) Product Revenue (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended			6 Months Ended
	Jun. 30, 2011	Jun. 30, 2010	Mar. 31, 2010	Jun. 30, 2011	Jun. 30, 2010
Product Revenue [Abstract]
Previously deferred ARCALYST net product sales recognized as revenue			$ 4,800		$ 4,800
Change in accounting estimate, deferred revenue - lower net loss per share (in dollars per share)					$ 0.06
ARCALYST net product sales	$ 5,039	$ 5,197		$ 9,466	$ 15,049
ARCALYST net product sales, excluding deferred sales recognized as revenue					10,200
Cost of goods sold related to ARCALYST sales	$ 395	$ 405		$ 777	$ 1,122

Per Share Data (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2011	Jun. 30, 2010	Jun. 30, 2011	Jun. 30, 2010
Basic and diluted net loss per share [Abstract]
Net loss (Numerator)	$ (62,505)	$ (25,474)	$ (105,952)	$ (55,996)
Weighted average shares outstanding, basic and diluted	90,436	81,492	89,799	81,330
Basic and diluted net loss per share (in dollars per share)	$ (0.69)	$ (0.31)	$ (1.18)	$ (0.69)
Stock Options [Member]
Antidilutive securities [Abstract]
Weighted average number, in thousands (in shares)	20,967	21,288	21,668	21,344
Weighted average exercise price (in dollars per share)	$ 20.71	$ 18.67	$ 20.48	$ 18.63
Restricted Stock [Member]
Antidilutive securities [Abstract]
Weighted average number, in thousands (in shares)	846	510	846	506

- Definition

Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 13, 14
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 171
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 40
-Subparagraph c
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Diluted Earnings Per Share
-URI http://asc.fasb.org/extlink&oid=6510752

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Contingent Stock Agreement
-URI http://asc.fasb.org/extlink&oid=6508534

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Antidilution
-URI http://asc.fasb.org/extlink&oid=6505113

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 07-4
-Paragraph 4
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 87-21
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph a
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 130
-Paragraph 10, 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 28, 29, 30
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Article 5
-Section 03
-Paragraph 19

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 20
-Article 9

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Net Income
-URI http://asc.fasb.org/extlink&oid=6518256

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Other Comprehensive Income
-URI http://asc.fasb.org/extlink&oid=6519514

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.18)
-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.19)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e565-108580

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.22)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph d
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph A7
-Appendix A

+ Details

Statement of Cash Flows (Details) - USD ($) shares in Thousands, $ in Millions	3 Months Ended		6 Months Ended
	Mar. 31, 2011	Mar. 31, 2010	Jun. 30, 2010	Jun. 30, 2011	Dec. 31, 2010	Dec. 31, 2009
Supplemental disclosure of noncash investing and financing activities [Abstract]
Accrued capital expenditures			$ 4.1	$ 3.4	$ 10.7	$ 9.8
Accrued Company 401(k) Savings Plan contribution expense					2.9	2.6
Common Stock contributed to 401(k) Savings Plan (in shares)	91,761	111,419
Capitalized and deferred interest			1.7
Capital lease obligations				0.7
Accrued interest income			$ 1.3	$ 0.8	$ 1.4	$ 0.6

Marketable Securities (Details) $ in Thousands	6 Months Ended
Marketable Securities (Details) $ in Thousands	Jun. 30, 2010 USD ($)	Jun. 30, 2011 USD ($) Integer	Dec. 31, 2010 USD ($) Integer
Debt Securities, Amortized Cost Basis [Abstract]
Amortized Cost Basis - Total		$ 309,768	$ 511,625
Debt Securities, Fair Value [Abstract]
Fair Value - Total		310,378	510,276
Unrealized Gains (Losses), Net [Abstract]
Unrealized Gains - Total		777	586
Unrealized (Losses) - Total		(167)	(1,935)
Unrealized Net - Total		610	(1,349)
Continuous Unrealized Loss Position, Fair Value [Abstract]
Fair Value - Less than 12 Months		30,344	369,215
Fair Value - 12 Months or Greater		207	1,128
Fair Value - Total		30,551	370,343
Continuous Unrealized Loss Position, Aggregate Losses [Abstract]
Unrealized Loss - Less than 12 Months		(26)	(2,227)
Unrealized Loss - 12 Months or Greater		(141)	(141)
Unrealized Loss - Total		$ (167)	$ (2,368)
Assets, fair value disclosure [Abstract]
Other-than-temporary impairment charge on Level 2 marketable security	$ 100
Number of Level 3 marketable securities held \| Integer		1	1
Fair Value Measurements at Reporting Date Using Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]
Assets, fair value disclosure [Abstract]
Available-for-sale marketable securities		$ 4,320	$ 3,612
Fair Value Measurements at Reporting Date Using Significant Other Observable Inputs (Level 2) [Member]
Assets, fair value disclosure [Abstract]
Available-for-sale marketable securities		310,378	510,276
Equity Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Fair value of equity securities		4,300	3,600
Cost basis of equity securities		4,000	4,000
Unrealized Gains (Losses), Net [Abstract]
Unrealized Gains - Total		300
Unrealized (Losses) - Total			(400)
Measured on a Recurring Basis [Member]
Assets, fair value disclosure [Abstract]
Available-for-sale marketable securities		314,698	513,888
Unrestricted [Member]
Debt Securities, Amortized Cost Basis [Abstract]
Amortized Cost Basis - Total		301,704	504,568
Debt Securities, Fair Value [Abstract]
Fair Value - Total		302,307	503,237
Unrealized Gains (Losses), Net [Abstract]
Unrealized Gains - Total		768	586
Unrealized (Losses) - Total		(165)	(1,917)
Unrealized Net - Total		603	(1,331)
Continuous Unrealized Loss Position, Fair Value [Abstract]
Fair Value - Less than 12 Months		28,913	363,061
Fair Value - 12 Months or Greater		207	1,128
Fair Value - Total		29,120	364,189
Continuous Unrealized Loss Position, Aggregate Losses [Abstract]
Unrealized Loss - Less than 12 Months		(24)	(2,209)
Unrealized Loss - 12 Months or Greater		(141)	(141)
Unrealized Loss - Total		(165)	(2,350)
Unrestricted [Member] \| Equity Securities [Member]
Continuous Unrealized Loss Position, Fair Value [Abstract]
Fair Value - Less than 12 Months			3,612
Fair Value - Total			3,612
Continuous Unrealized Loss Position, Aggregate Losses [Abstract]
Unrealized Loss - Less than 12 Months			(433)
Unrealized Loss - Total			(433)
Unrestricted [Member] \| U.S. Government Obligations [Member]
Debt Securities, Amortized Cost Basis [Abstract]
Amortized Cost Basis - Maturities within one year		9,142	83,635
Amortized Cost Basis - Maturities between one and five years		227,542	352,345
Debt Securities, Fair Value [Abstract]
Fair Value - Maturities within one year		9,159	83,684
Fair Value - Maturities between one and five years		228,070	350,683
Unrealized Gains (Losses), Net [Abstract]
Unrealized Gains - Maturities within one year		17	54
Unrealized Gains - Maturities between one and five years		551	64
Unrealized (Losses) - Maturities within one year			(5)
Unrealized (Losses) - Maturities between one and five years		(23)	(1,726)
Unrealized Net - Maturities within one year		17	49
Unrealized Net - Maturities between one and five years		528	(1,662)
Continuous Unrealized Loss Position, Fair Value [Abstract]
Fair Value - Less than 12 Months		25,649	340,444
Fair Value - Total		25,649	340,444
Continuous Unrealized Loss Position, Aggregate Losses [Abstract]
Unrealized Loss - Less than 12 Months		(23)	(1,731)
Unrealized Loss - Total		(23)	(1,731)
Unrestricted [Member] \| U.S. Government Guaranteed Corporate Bonds [Member]
Debt Securities, Amortized Cost Basis [Abstract]
Amortized Cost Basis - Maturities within one year		31,936	48,173
Amortized Cost Basis - Maturities between one and five years		15,393	15,522
Debt Securities, Fair Value [Abstract]
Fair Value - Maturities within one year		32,088	48,531
Fair Value - Maturities between one and five years		15,408	15,477
Unrealized Gains (Losses), Net [Abstract]
Unrealized Gains - Maturities within one year		152	358
Unrealized Gains - Maturities between one and five years		15
Unrealized (Losses) - Maturities between one and five years			(45)
Unrealized Net - Maturities within one year		152	358
Unrealized Net - Maturities between one and five years		15	(45)
Continuous Unrealized Loss Position, Fair Value [Abstract]
Fair Value - Less than 12 Months			19,005
Fair Value - Total			19,005
Continuous Unrealized Loss Position, Aggregate Losses [Abstract]
Unrealized Loss - Less than 12 Months			(45)
Unrealized Loss - Total			(45)
Unrestricted [Member] \| Mortgage-Backed Securities [Member]
Debt Securities, Amortized Cost Basis [Abstract]
Amortized Cost Basis - Maturities within one year		73	875
Amortized Cost Basis - Maturities between one and five years		275	110
Amortized Cost Basis - Maturities between five and seven years			284
Debt Securities, Fair Value [Abstract]
Fair Value - Maturities within one year		72	847
Fair Value - Maturities between one and five years		135	38
Fair Value - Maturities between five and seven years			243
Unrealized Gains (Losses), Net [Abstract]
Unrealized (Losses) - Maturities within one year		(1)	(28)
Unrealized (Losses) - Maturities between one and five years		(140)	(72)
Unrealized (Losses) - Maturities between five and seven years			(41)
Unrealized Net - Maturities within one year		(1)	(28)
Unrealized Net - Maturities between one and five years		(140)	(72)
Unrealized Net - Maturities between five and seven years			(41)
Continuous Unrealized Loss Position, Fair Value [Abstract]
Fair Value - 12 Months or Greater		207	1,128
Fair Value - Total		207	1,128
Continuous Unrealized Loss Position, Aggregate Losses [Abstract]
Unrealized Loss - 12 Months or Greater		(141)	(141)
Unrealized Loss - Total		(141)	(141)
Unrestricted [Member] \| U.S. Government Guaranteed Collateralized Mortgage Obligations [Member]
Debt Securities, Amortized Cost Basis [Abstract]
Amortized Cost Basis - Maturities within one year		1,321	2,027
Debt Securities, Fair Value [Abstract]
Fair Value - Maturities within one year		1,322	2,131
Unrealized Gains (Losses), Net [Abstract]
Unrealized Gains - Maturities within one year		1	104
Unrealized Net - Maturities within one year		1	104
Unrestricted [Member] \| Municipal Bonds [Member]
Debt Securities, Amortized Cost Basis [Abstract]
Amortized Cost Basis - Maturities within one year		12,712	1,597
Amortized Cost Basis - Maturities between one and five years		3,310
Debt Securities, Fair Value [Abstract]
Fair Value - Maturities within one year		12,730	1,603
Fair Value - Maturities between one and five years		3,323
Unrealized Gains (Losses), Net [Abstract]
Unrealized Gains - Maturities within one year		19	6
Unrealized Gains - Maturities between one and five years		13
Unrealized (Losses) - Maturities within one year		(1)
Unrealized Net - Maturities within one year		18	6
Unrealized Net - Maturities between one and five years		13
Continuous Unrealized Loss Position, Fair Value [Abstract]
Fair Value - Less than 12 Months		3,264
Fair Value - Total		3,264
Continuous Unrealized Loss Position, Aggregate Losses [Abstract]
Unrealized Loss - Less than 12 Months		(1)
Unrealized Loss - Total		(1)
Unrestricted [Member] \| Debt Securities [Member]
Debt Securities, Amortized Cost Basis [Abstract]
Amortized Cost Basis - Maturities within one year		55,184	136,307
Amortized Cost Basis - Maturities between one and five years		246,520	367,977
Debt Securities, Fair Value [Abstract]
Fair Value - Maturities within one year		55,371	136,796
Fair Value - Maturities between one and five years		246,936	366,198
Unrealized Gains (Losses), Net [Abstract]
Unrealized Gains - Maturities within one year		189	522
Unrealized Gains - Maturities between one and five years		579	64
Unrealized (Losses) - Maturities within one year		(2)	(33)
Unrealized (Losses) - Maturities between one and five years		(163)	(1,843)
Unrealized Net - Maturities within one year		187	489
Unrealized Net - Maturities between one and five years		416	(1,779)
Unrestricted [Member] \| Measured on a Recurring Basis [Member]
Assets, fair value disclosure [Abstract]
U.S. government obligations		237,229	434,367
U.S. government guaranteed corporate bonds		47,496	64,008
U.S. government guaranteed collateralized mortgage obligations		1,322	2,131
Municipal bonds		16,053	1,603
Mortgage-backed securities		207	1,128
Equity securities		4,320	3,612
Available-for-sale marketable securities		306,627	506,849
Unrestricted [Member] \| Measured on a Recurring Basis [Member] \| Fair Value Measurements at Reporting Date Using Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]
Assets, fair value disclosure [Abstract]
Equity securities		4,320	3,612
Available-for-sale marketable securities		4,320	3,612
Unrestricted [Member] \| Measured on a Recurring Basis [Member] \| Fair Value Measurements at Reporting Date Using Significant Other Observable Inputs (Level 2) [Member]
Assets, fair value disclosure [Abstract]
U.S. government obligations		237,229	434,367
U.S. government guaranteed corporate bonds		47,496	64,008
U.S. government guaranteed collateralized mortgage obligations		1,322	2,131
Municipal bonds		16,053	1,603
Mortgage-backed securities		207	1,128
Available-for-sale marketable securities		302,307	503,237
Restricted [Member]
Debt Securities, Amortized Cost Basis [Abstract]
Amortized Cost Basis - Total		8,064	7,057
Debt Securities, Fair Value [Abstract]
Fair Value - Total		8,071	7,039
Unrealized Gains (Losses), Net [Abstract]
Unrealized Gains - Total		9
Unrealized (Losses) - Total		(2)	(18)
Unrealized Net - Total		7	(18)
Continuous Unrealized Loss Position, Fair Value [Abstract]
Fair Value - Less than 12 Months		1,431	6,154
Fair Value - Total		1,431	6,154
Continuous Unrealized Loss Position, Aggregate Losses [Abstract]
Unrealized Loss - Less than 12 Months		(2)	(18)
Unrealized Loss - Total		(2)	(18)
Restricted [Member] \| U.S. Government Obligations [Member]
Debt Securities, Amortized Cost Basis [Abstract]
Amortized Cost Basis - Maturities within one year		2,888	2,922
Amortized Cost Basis - Maturities between one and three years		5,176	4,135
Debt Securities, Fair Value [Abstract]
Fair Value - Maturities within one year		2,889	2,921
Fair Value - Maturities between one and three years		5,182	4,118
Unrealized Gains (Losses), Net [Abstract]
Unrealized Gains - Maturities within one year		1
Unrealized Gains - Maturities between one and three years		8
Unrealized (Losses) - Maturities within one year			(1)
Unrealized (Losses) - Maturities between one and three years		(2)	(17)
Unrealized Net - Maturities within one year		1	(1)
Unrealized Net - Maturities between one and three years		6	(17)
Continuous Unrealized Loss Position, Fair Value [Abstract]
Fair Value - Less than 12 Months		1,431	6,154
Fair Value - Total		1,431	6,154
Continuous Unrealized Loss Position, Aggregate Losses [Abstract]
Unrealized Loss - Less than 12 Months		(2)	(18)
Unrealized Loss - Total		(2)	(18)
Restricted [Member] \| Measured on a Recurring Basis [Member]
Assets, fair value disclosure [Abstract]
U.S. government obligations		8,071	7,039
Restricted [Member] \| Measured on a Recurring Basis [Member] \| Fair Value Measurements at Reporting Date Using Significant Other Observable Inputs (Level 2) [Member]
Assets, fair value disclosure [Abstract]
U.S. government obligations		$ 8,071	$ 7,039

Inventory (Details) - USD ($) $ in Thousands	Jun. 30, 2011	Dec. 31, 2010
Inventory [Abstract]
Raw materials	$ 223	$ 592
Work in process	6,188	699
Finished goods	131	132
Total inventories	6,542	$ 1,423
Inventories included in prepaid expenses and other current assets	600
Inventories included in other assets	$ 5,900

Accounts Payable and Accrued Expenses (Details) - USD ($) $ in Thousands	Jun. 30, 2011	Dec. 31, 2010
Accounts payable and accrued expenses [Abstract]
Accounts payable	$ 25,955	$ 15,589
Accrued payroll and related costs	26,029	12,025
Accrued clinical trial expense	9,802	9,727
Accrued property, plant, and equipment costs	1,057	7,622
Other accrued expenses and liabilities	7,810	6,441
Payable to Bayer HealthCare	11,012	2,254
Accounts payable and accrued expenses	$ 81,665	$ 53,658

- Definition

Carrying value as of the balance sheet date of obligations incurred through that date and payable arising from transactions not otherwise specified in the taxonomy. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References + Details

Comprehensive Loss (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
Comprehensive Loss (Details) - USD ($) $ in Thousands	Jun. 30, 2011	Jun. 30, 2010	Jun. 30, 2011	Jun. 30, 2010
Components of comprehensive loss, net of tax [Abstract]
Net loss	$ (62,505)	$ (25,474)	$ (105,952)	$ (55,996)
Change in net unrealized gain (loss) on marketable securities	1,271	(1,023)	1,587	(1,350)
Total comprehensive loss	(61,234)	$ (26,497)	(104,365)	$ (57,346)
Change in net unrealized gain (loss) on marketable securities, net of tax effect	$ 900		$ 1,100

- Definition

The change in equity [net assets] of a business enterprise during a period from transactions and other events and circumstances from non-owner sources which are attributable to the reporting entity. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners, but excludes any and all transactions which are directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 8, 9, 10, 11, 12, 13, 14
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 30
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph A5
-Appendix A

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e557-108580

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Net Income
-URI http://asc.fasb.org/extlink&oid=6518256

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Other Comprehensive Income
-URI http://asc.fasb.org/extlink&oid=6519514

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e540-108580

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Comprehensive Income
-URI http://asc.fasb.org/extlink&oid=6508144

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph c(3)
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

+ Details

- Definition

Appreciation or loss in value (before reclassification adjustment) of the total of unsold securities during the period being reported on, net of tax. Reclassification adjustments include: (1) the unrealized holding gain (loss), net of tax, at the date of the transfer for a debt security from the held-to-maturity category transferred into the available-for-sale category. Also includes the unrealized gain (loss) at the date of transfer for a debt security from the available-for-sale category transferred into the held-to-maturity category; (2) the unrealized gains (losses) realized upon the sale of securities, after tax; and (3) the unrealized gains (losses) realized upon the write-down of securities, after tax.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 115
-Paragraph 13
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 130
-Paragraph 24
-Subparagraph b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 130
-Paragraph 17, 22
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e637-108580

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e653-108580

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 55
-Paragraph 2
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=6920433&loc=d3e998-108581

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph c(3)
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Income Taxes (Details) - USD ($) $ in Millions	3 Months Ended	6 Months Ended
Income Taxes (Details) - USD ($) $ in Millions	Jun. 30, 2011	Jun. 30, 2011
Income Taxes [Abstract]
Change in net unrealized gain (loss) on marketable securities, net of tax effect	$ 0.9	$ 1.1

Recently Issued Accounting Standards (Details) $ in Millions	6 Months Ended
	Jun. 30, 2011 USD ($) Integer
Collaboration Agreement with Sanofi-Aventis [Member]
Revenue Recognition, Milestone Method [Line Items]
Description of the overall arrangement	<div>jointly develop and commercialize ZALTRAP<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">TM</font> (aflibercept, also known as VEGF Trap)</div>
Description of milestone	<div>substantive milestone payments upon receipt of specified marketing approvals</div>
Maximum amount of substantive milestone payments that may be received	$ 400
Maximum amount of substantive milestone payments that may be received relating to marketing approvals in the U.S. or European Union	$ 360
Maximum number of product candidates for which substantive milestone payments may be received relating to marketing approvals in the U.S. or European Union \| Integer	8
Maximum amount of substantive milestone payments that may be received relating to marketing approvals in Japan	$ 40
Maximum number of product candidates for which substantive milestone payments may be received relating to marketing approvals in Japan \| Integer	5
The amount of substantive milestone payment to be made by the collaborating company to the entity, under certain defined circumstances.	$ 10
Collaboration Agreement with Bayer HealthCare LLC [Member]
Revenue Recognition, Milestone Method [Line Items]
Description of the overall arrangement	<div>globally develop, and commercialize outside the U.S., the Company's VEGF Trap for the treatment of eye disease by local administration EYLEA<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">TM</font></div>
Description of milestone	<div>substantive milestone payments related to marketing approvals of EYLEA<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">TM</font> in major market countries outside the US</div>
The amount of substantive milestone payment to be made by the collaborating company to the entity, under certain defined circumstances.	$ 50